Connect with us

Healthcare

‘Operation Warp Speed’: Dr. Fauci Says Developing A COVID Vaccine By January Is ‘Doable’

Published

on

Screenshot 2020 04 30 10.03.04

The Director of the National Institute of Allergy and Infectious Diseases and member of the White House Coronavirus Task Force Dr. Anthony Fauci told the Today Show’s Savannah Guthrie Thursday that developing a vaccine to combat the coronavirus outbreak by January is “doable.”

“What the plan is right now is, as I mentioned to you a couple of times on this show, we’re in the early phases of a trial, Phase 1. When you go into the next phase, we’re gonna safely and carefully, but as quickly as we possibly can, try and get an answer as to whether it works and is safe,” Fauci said.

He added, “And, if so, we’re gonna start ramping up production with the companies involved. And you do that at risk. In other words, you don’t wait until you get an answer before you start manufacturing. You at risk proactively start making it assuming it’s gonna work, and, if it does, then you could scale up and hopefully get to that timeline. So we want to go quickly, but we want to make sure it’s safe and it’s effective.”

The Trump Administration announced “Operation Warp Speed” to accelerate the development of a vaccine, Bloomberg News first reported Wednesday.

The report states. “The project’s goal is to have 300 million doses of vaccine available by January, according to one administration official. There is no precedent for such rapid development of a vaccine.”

 

You may like

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

China

FDA will work with China to import cancer drugs due to U.S. shortages

Published

on

FinalFDAshutterstock 1044596995

Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.

Foreign Desk News writes:

Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.

“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.

Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.

“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.

Foreign Desk News adds:

The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.

 

You may like

Continue Reading
Advertisement
-->

Trending Now

Advertisement
-->

Trending